文献速递冠心病血脂与心血管预防

跨祖先蛋白质组遗传分析为缺血性心脏病提供新治疗见解

Cross-Ancestry Proteogenomic Analyses Identified New Therapeutic Insights for Ischemic Heart Disease.
PubMed 文献 · J Am Coll Cardiol · 2026-07-29

研究在无他汀治疗的中国慢性病前瞻性研究病例队列中测量9520种血浆蛋白,通过顺式pQTL、孟德尔随机化和共定位分析探索缺血性心脏病(IHD)的潜在药物靶点。东亚人群中15种蛋白获共定位支持,欧洲人群中12种非酒精相关蛋白中8种方向一致、5种共定位证据强,但部分蛋白方向不一致,提示需跨祖先验证。

要点

  • 东亚人群中15种蛋白获共定位证据支持与IHD相关,包括8种脂质相关、3种炎症相关、1种血压相关和3种酒精相关蛋白。
  • 欧洲人群中12种非酒精相关蛋白的MR结果有8种方向一致,其中5种共定位证据强(PPH4≥0.8)。
  • 4种蛋白在欧洲人群中MR方向不一致,包括APOA5、SORT1和TGFB1,提示靶点效应可能存在祖先差异。

核心结论

  • 研究结果支持脂质驱动的慢性炎症在IHD病因中的作用,建议优先研究同时靶向多个脂质和炎症通路的治疗策略。

研究设计与样本

  • 基于中国慢性病前瞻性研究(CKB)的病例队列设计,纳入1976例IHD incident cases和2001例亚队列对照,均为无他汀治疗个体。
  • 测量9520种血浆蛋白(Olink 2923种,SomaScan 7297种),在CKB中全基因组关联分析鉴定2895个顺式pQTL。
  • 采用两样本孟德尔随机化和共定位分析评估顺式pQTL与IHD的关联,在东亚人群(29319例病例)中分析,并在欧洲人群(181522例病例)中重复验证。

主要发现

  • CKB观察性分析中,959种蛋白(Olink 426种,SomaScan 533种)在校正主要IHD危险因素后与IHD关联(FDR校正P<0.05)。
  • 两样本MR分析为54种独特蛋白(Olink 36种,SomaScan 28种)与IHD病因关联提供遗传学支持。
  • 共定位分析确认15种独特蛋白(Olink 10种,SomaScan 10种)存在共享基因-蛋白-IHD关联(PPH4≥0.8),包括8种脂质相关、3种炎症相关、1种血压相关和3种酒精相关蛋白。
  • 欧洲人群中12种非酒精相关蛋白的MR分析显示8种方向一致,其中5种共定位证据强(PPH4≥0.8),包括4种脂质相关蛋白(PCSK9、LPA、APOE、cadherin-1)和1种收缩压相关蛋白(FGF5)。
  • 4种蛋白在欧洲人群中MR结果方向不一致,包括2种脂质相关蛋白(APOA5、SORT1)和1种炎症相关蛋白(TGFB1),且具有强共定位证据(PPH4≥0.8)。

关键数值与推荐

  • 共定位共享关联的判定标准为假设4的后验概率(PPH4)≥0.8。
  • 观察性关联的显著性标准为FDR校正P<0.05。

临床怎么用

  • 研究提示可优先探索同时靶向多个脂质和炎症通路的治疗策略,以改善他汀治疗之外的IHD药物治疗。
  • 跨祖先MR分析结果提示部分蛋白靶点(如APOA5、SORT1、TGFB1)的效应可能存在人群差异,药物开发需考虑祖先背景。

局限性

  • 与既往MR研究比较,除已明确的脂质相关(LDL-C、Lp(a)、甘油三酯)或炎症相关(IL-6)靶点外,研究间在靶点数量和身份上一致性较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most drugs target proteins, and proteome-wide genetic analyses in diverse populations could discover potential novel and repurposed targets for improved prevention and treatment of ischemic heart disease (IHD) beyond statin therapy. OBJECTIVES: The purposes of this study were to use cis-acting single nucleotide polymorphisms (cis-pQTLs) identified for plasma proteins in East Asians and Europeans to discover and validate potential drug targets for IHD. METHODS: We measured plasma levels of 9,520 (Olink/SomaScan: 2,923/7,297) proteins in a case-cohort study of IHD (1,976 incident cases and 2,001 subcohort controls) in statin-free individuals in the prospective China Kadoorie Biobank (CKB). Genome-wide association studies identified 2,895 (Olink/SomaScan: 1,301/1,594) cis-pQTLs for these proteins in CKB. Two-sample Mendelian randomization (MR) and colocalization analyses assessed associations of all available cis-pQTLs for these proteins with IHD in East Asians (n = 29,319 cases), with further replication in Europeans (n = 181,522 cases) and comparison with findings in previous MR studies. RESULTS: In CKB observational analyses, a total of 959 (Olink/SomaScan: 426/533) proteins were associated at false discovery rate-corrected P < 0.05 with IHD after adjusting for major IHD risk factors. Two-sample MR analyses provided genetic support for 54 unique (Olink/SomaScan: 36/28) proteins in IHD etiology. Colocalization analyses confirmed shared gene-protein-IHD associations (posterior probability of hypothesis 4 [PPH4] ≥0.8) for 15 unique (Olink/SomaScan: 10/10) proteins, including 8 lipid-related, 3 inflammation-related, 1 blood pressure-related, and 3 alcohol-related proteins in East Asians. In Europeans, MR analyses of 12 non-alcohol-related proteins showed directionally concordant results for 8 proteins, with 5 having strong colocalization evidence of shared gene-protein-IHD associations (PPH4 ≥0.8), including 4 lipid-related (proprotein convertase subtilisin/kexin type 9, LPA, APOE, cadherin-1) and 1 systolic blood pressure-related (fibroblast growth factor 5) protein. However, 4 proteins showed directionally discordant MR results, including 2 lipid-related (APOA5, SORT1) and 1 inflammation-related (transforming growth factor beta 1) proteins with strong colocalization evidence of shared gene-protein-IHD associations (PPH4 ≥0.8). Comparison with previous MR studies revealed little consistency across studies in the number and identity of target proteins for IHD beyond well-established lipid-related (low-density lipoprotein cholesterol, lipoprotein(a), and triglycerides) or inflammation-related (interleukin-6) protein targets. CONCLUSIONS: The findings support a role for lipid-driven chronic inflammation in IHD etiology, and treatment strategies simultaneously targeting multiple lipid and inflammation pathways should be prioritized for further research to improve drug treatment of IHD beyond statin therapy.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mazidi M, Wright N, Pozarickij A, et al. Cross-Ancestry Proteogenomic Analyses Identified New Therapeutic Insights for Ischemic Heart Disease. J Am Coll Cardiol. 2026. PMID: 42524807. doi:10.1016/j.jacc.2026.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。